PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to explore the role of PD-1 Antibody in preventing adenomatous polyps and
second primary tumors in patients with Lynch Syndrome. There two arms, one is the
experimental arm (PD-1 antibody prevention group) and the other is the control arm (routine
follow-up group). For the experimental group, Tripleitriumab (PD-1 antibody) is given every 3
months for a year.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Fujian Cancer Hospital Guangdong Provincial Hospital of Traditional Chinese Medicine Guangdong Provincial People's Hospital Second Affiliated Hospital, School of Medicine, Zhejiang University The Third Affiliated Hospital of Kunming Medical College.